{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:20:34Z","timestamp":1793578834114,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01642-1","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T21:52:08Z","timestamp":1734645128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects"],"prefix":"10.1186","volume":"16","author":[{"given":"Francisco","family":"Mart\u00ednez-Dubarbie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Guerra-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"L\u00f3pez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fern\u00e1ndez-Matarrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pozueta-Cantudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Corrales-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"L\u00f3pez-Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Irure-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Marco","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Drake-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Garc\u00eda-Unzueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascual","family":"S\u00e1nchez-Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloy","family":"Rodr\u00edguez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"3","key":"1642_CR1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/archneur.55.3.326","volume":"55","author":"L Berg","year":"1998","unstructured":"Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer\u2019s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326\u201335. https:\/\/doi.org\/10.1001\/archneur.55.3.326.","journal-title":"Arch Neurol"},{"issue":"4","key":"1642_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1642_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n J, Leuzy A, Karikari TK, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2021;17(7):1145\u201356. https:\/\/doi.org\/10.1002\/alz.12283.","journal-title":"Alzheimers Dement"},{"issue":"7691","key":"1642_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354. https:\/\/doi.org\/10.1038\/nature25456.","journal-title":"Nature"},{"issue":"12","key":"1642_CR5","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1002\/alz.13455","volume":"19","author":"K Blennow","year":"2023","unstructured":"Blennow K, Galasko D, Perneczky R, et al. The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(12):5805\u201316. https:\/\/doi.org\/10.1002\/alz.13455.","journal-title":"Alzheimers Dement"},{"key":"1642_CR6","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. Published online June. 2024;27. https:\/\/doi.org\/10.1002\/alz.13859.","DOI":"10.1002\/alz.13859"},{"issue":"9","key":"1642_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w.","journal-title":"Nat Med"},{"issue":"8","key":"1642_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020;324(8):772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"issue":"5","key":"1642_CR9","doi-asserted-by":"publisher","first-page":"e17123","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med. 2023;15(5):e17123. https:\/\/doi.org\/10.15252\/emmm.202217123.","journal-title":"EMBO Mol Med"},{"issue":"10","key":"1642_CR10","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1002\/alz.13393","volume":"19","author":"PCL Ferreira","year":"2023","unstructured":"Ferreira PCL, Therriault J, Tissot C, et al. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement. 2023;19(10):4463\u201374. https:\/\/doi.org\/10.1002\/alz.13393.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1642_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1642_CR12","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain. 2020;143(11):3234\u201341. https:\/\/doi.org\/10.1093\/brain\/awaa286.","journal-title":"Brain"},{"issue":"4","key":"1642_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. 2023;80(4):360\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1642_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimer\u2019s Dement. 2023;19(5):1913\u201324. https:\/\/doi.org\/10.1002\/alz.12841.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1642_CR15","doi-asserted-by":"publisher","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler S, et al. Highly Accurate Blood Test for Alzheimer\u2019s Disease Comparable or Superior to Clinical CSF Tests. Nat Med Published online Febr. 2024;21. https:\/\/doi.org\/10.1038\/s41591-024-02869-z.","DOI":"10.1038\/s41591-024-02869-z"},{"key":"1642_CR16","doi-asserted-by":"publisher","unstructured":"Cullen NC, Janelidze S, Mattsson-Carlgren N, et al. Test-retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models. Alzheimers Dement Published online June. 2022;14. https:\/\/doi.org\/10.1002\/alz.12706.","DOI":"10.1002\/alz.12706"},{"key":"1642_CR17","doi-asserted-by":"publisher","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios [published correction appears in JAMA Neurol. 2023;80(8):873. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1932]. JAMA Neurol. 2023;80(5):516\u2013522. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199.","DOI":"10.1001\/jamaneurol.2023.1932 10.1001\/jamaneurol.2023.0199"},{"issue":"4","key":"1642_CR18","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146(4):1592\u2013601. https:\/\/doi.org\/10.1093\/brain\/awac333.","journal-title":"Brain"},{"issue":"1","key":"1642_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13(1):198. https:\/\/doi.org\/10.1186\/s13195-021-00939-9. Published 2021 Dec 4.","journal-title":"Alzheimers Res Ther"},{"key":"1642_CR20","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J, Ashton NJ, Pola I, et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. EBioMedicine. 2024;102:105046. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105046.","journal-title":"EBioMedicine"},{"key":"1642_CR21","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.152","author":"F Mart\u00ednez-Dubarbie","year":"2024","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, et al. Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform. J Prev Alzheimers Dis. 2024. https:\/\/doi.org\/10.14283\/jpad.2024.152.","journal-title":"J Prev Alzheimers Dis"},{"key":"1642_CR22","doi-asserted-by":"publisher","unstructured":"Arranz J, Zhu N, Rubio-Guerra S et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21\u201342 and A\u03b21\u201340 in the LUMIPULSE automated platform for the detection of Alzheimer disease [published correction appears in Alzheimers Res Ther. 2024;16(1):168. doi: 10.1186\/s13195-024-01538-0]. Alzheimers Res Ther. 2024;16(1):139. Published 2024 Jun 26. https:\/\/doi.org\/10.1186\/s13195-024-01513-9","DOI":"10.1186\/s13195-024-01513-9"},{"issue":"9","key":"1642_CR23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023;3(9):1079\u201390. https:\/\/doi.org\/10.1038\/s43587-023-00471-5.","journal-title":"Nat Aging"},{"issue":"2","key":"1642_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, et al. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80(2):188\u201399. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485.","journal-title":"JAMA Neurol"},{"key":"1642_CR25","doi-asserted-by":"publisher","unstructured":"Groot C, Cicognola C, Bali D et al. Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217 [published correction appears in Alzheimers Res Ther. 2022;14(1):82. doi: 10.1186\/s13195-022-01023-6]. Alzheimers Res Ther. 2022;14(1):67. Published 2022 May 14. https:\/\/doi.org\/10.1186\/s13195-022-01005-8","DOI":"10.1186\/s13195-022-01005-8"},{"issue":"4","key":"1642_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.14283\/jpad.2024.134","volume":"11","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Donohue MC, Langford O, et al. Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2024;11(4):823\u201330. https:\/\/doi.org\/10.14283\/jpad.2024.134.","journal-title":"J Prev Alzheimers Dis"},{"issue":"11","key":"1642_CR27","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a.","journal-title":"Neurology"},{"issue":"3","key":"1642_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"4\u20135","key":"1642_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clinbiochem.2013.12.024","volume":"47","author":"CE Teunissen","year":"2014","unstructured":"Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem. 2014;47(4\u20135):288\u201392. https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.12.024.","journal-title":"Clin Biochem"},{"issue":"4","key":"1642_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Andreasson U, Persson S, et al. The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7(4):386\u2013e3956. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2243.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1642_CR31","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484\u201397. https:\/\/doi.org\/10.1002\/alz.12510.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1642_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom J, Parnetti L, Rosa-Neto P, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2022;60(2):207\u201319. https:\/\/doi.org\/10.1515\/cclm-2021-0651.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"1642_CR33","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archneurol.2010.179","volume":"67","author":"G De Meyer","year":"2010","unstructured":"De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949\u201356. https:\/\/doi.org\/10.1001\/archneurol.2010.179.","journal-title":"Arch Neurol"},{"issue":"5","key":"1642_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347. https:\/\/doi.org\/10.1212\/WNL.0000000000002923.","journal-title":"Neurology"},{"issue":"9","key":"1642_CR35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"key":"1642_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00265-010-1029-6","volume":"65","author":"KP Burnham","year":"2011","unstructured":"Burnham KP, Anderson DR, Huyvaert KP. AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons. Behav Ecol Sociobiol. 2011;65:23\u201335. https:\/\/doi.org\/10.1007\/s00265-010-1029-6.","journal-title":"Behav Ecol Sociobiol"},{"issue":"7","key":"1642_CR37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.18553\/jmcp.2020.26.7.888","volume":"26","author":"A Hung","year":"2020","unstructured":"Hung A, Schneider M, Lopez MH, McClellan M. Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials. J Manag Care Spec Pharm. 2020;26(7):888\u2013900. https:\/\/doi.org\/10.18553\/jmcp.2020.26.7.888.","journal-title":"J Manag Care Spec Pharm"},{"key":"1642_CR38","doi-asserted-by":"publisher","unstructured":"Du L, Langhough RE, Wilson RE, et al. Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a non-demented Alzheimer\u2019s risk-enhanced sample. Alzheimers Dement Published online July. 2024;5. https:\/\/doi.org\/10.1002\/alz.14100.","DOI":"10.1002\/alz.14100"},{"key":"1642_CR39","doi-asserted-by":"publisher","unstructured":"Fortea J, Pegueroles J, Alcolea D et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer\u2019s disease [published correction appears in Nat Med. 2024;30(7):2093. doi: 10.1038\/s41591-024-03127-y]. Nat Med. 2024;30(5):1284\u20131291. https:\/\/doi.org\/10.1038\/s41591-024-02931-w","DOI":"10.1038\/s41591-024-02931-w"},{"issue":"12","key":"1642_CR40","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28(12):2555\u201362. https:\/\/doi.org\/10.1038\/s41591-022-02074-w.","journal-title":"Nat Med"},{"issue":"3","key":"1642_CR41","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/ijms25031481","volume":"25","author":"F Mart\u00ednez-Dubarbie","year":"2024","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, et al. Influence of Physiological Variables and Comorbidities on Plasma A\u03b240, A\u03b242, and p-tau181 Levels in Cognitively Unimpaired Individuals. Int J Mol Sci. 2024;25(3):1481. https:\/\/doi.org\/10.3390\/ijms25031481. Published 2024 Jan 25.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1642_CR42","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren N, Grinberg LT, Boxer A, et al. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology. 2022;98(11):e1137\u201350. https:\/\/doi.org\/10.1212\/WNL.0000000000200040.","journal-title":"Neurology"},{"issue":"7","key":"1642_CR43","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1642_CR44","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Mu\u00f1oz L, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815\u201324. https:\/\/doi.org\/10.1002\/acn3.50873.","journal-title":"Ann Clin Transl Neurol"},{"key":"1642_CR45","doi-asserted-by":"publisher","unstructured":"Moon S, Kim S, Mankhong S et al. Alzheimer\u2019s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans. Alzheimers Res Ther. 2021;13(1):22. Published 2021 Jan 12. https:\/\/doi.org\/10.1186\/s13195-020-00767-3","DOI":"10.1186\/s13195-020-00767-3"},{"issue":"1","key":"1642_CR46","doi-asserted-by":"publisher","first-page":"e12131","DOI":"10.1002\/dad2.12131","volume":"13","author":"A Keshavan","year":"2021","unstructured":"Keshavan A, Wellington H, Chen Z, et al. Concordance of CSF measures of Alzheimer\u2019s pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimers Dement (Amst). 2021;13(1):e12131. https:\/\/doi.org\/10.1002\/dad2.12131. Published 2021 Feb 6.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1642_CR47","doi-asserted-by":"publisher","unstructured":"Jansen WJ, Janssen O, Tijms BM et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum [published correction appears in JAMA Neurol. 2022;79(3):313. doi: 10.1001\/jamaneurol.2022.0265]. JAMA Neurol. 2022;79(3):228\u2013243. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5216","DOI":"10.1001\/jamaneurol.2021.5216"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01642-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T22:05:12Z","timestamp":1734645912000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01642-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research has been conducted in accordance with the Declaration of Helsinki and has been approved by the ethics committee of the Hospital Universitario Marqu\u00e9s de Valdecilla. Title: Valdecilla Cohort for the study of memory and brain aging. Internal code: 2018.111. All subjects have given their signed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}